Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is a global conglomerate that specializes in manufacturing scientific instruments and consumables for the life sciences and diagnostic industries. Their diversified portfolio of businesses provides a solid foundation for future growth, and their focus on innovation and cutting-edge technology positions them well in the market. Additionally, their strong management team and track record of successful mergers and acquisitions bode well for future growth opportunities.

Bears say

Danaher is a successful industrial manufacturing company that has transformed and diversified through mergers, acquisitions, and divestitures. However, recent performance in its biotechnology segment, specifically with consumables growth, has been disappointing due to large shipments being delayed. This, combined with potential industry-level dynamics and increasing competition, may hinder Danaher's projected growth potential. Despite a historically high valuation and recent improvements in management diversity and sustainability efforts, there are still risks such as sluggish economic recovery and challenges with acquisition integration.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.